Yayınlar & Eserler

Yayın Ağı
Makaleler 33
Tümü (33)
SCI-E, SSCI, AHCI (31)
SCI-E, SSCI, AHCI, ESCI (32)
ESCI (1)
Scopus (33)
TRDizin (1)

1. Codelivery of nivolumab and galunisertib by EGFR-targeted spherical polymeric nanoparticles for effective treatment of non-small cell lung cancer

Kaplan M., TAVUKÇUOĞLU DEMİR E., ÖZTÜRK S. C., ÇALIŞ S., ESENDAĞLI G., Ozturk K.
International Journal of Pharmaceutics , cilt.703, 2026 (SCI-Expanded, Scopus)

2. Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity

Hanifehnezhad A., Oztop S., TAVUKÇUOĞLU DEMİR E., Tanyeri Y., Yoyler E., Gokce Tepeli G., et al.
Scientific reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

3. Differential modulation of exhausted Th1 cell migration by immune checkpoint blockade: insights from 3D microfluidic and in vivo PDX platforms

Horzum U., Yanik H., Tavukcuoglu E., TAŞKIRAN Z. E., ÖZTÜRK S. C., YILMAZ K., et al.
Lab on a Chip , cilt.26, sa.17, ss.4788-4801, 2026 (SCI-Expanded, Scopus)

4. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model

YILMAZ K., Tavukcuoglu E., Yanik H., Seçken P., Celik E., Guler S., et al.
Medicina (Lithuania) , cilt.62, sa.3, 2026 (SCI-Expanded, Scopus)

5. Spaceflight alters the immune regulatory functions of neutrophil granulocytes on T lymphocytes

Tavukçuoğlu E., Yanık H., Güven H. E., Yılmaz K. B., ESENDAĞLI G.
iScience , cilt.29, sa.1, 2026 (SCI-Expanded, Scopus)

6. The impact of aspirin on PD-L1 expression and alteration of M2 polarization in non-small cell lung cancer

Unver N., Uluturk S., Tavukcuoglu E., Duymaz Yilmaz E., Kaymaz Y., Esendagli G.
Inflammation Research , cilt.74, sa.1, 2025 (SCI-Expanded, Scopus)

7. CD66b+ Tumor-Infiltrating Neutrophil-like Monocytes as Potential Biomarkers for Clinical Decision-Making in Thyroid Cancer

Yanik H., Demir I., Celik E., Tavukcuoglu E., Bahcecioglu I. B., Bahcecioglu A. B., et al.
Medicina (Lithuania) , cilt.61, sa.7, 2025 (SCI-Expanded, Scopus)

8. IL-8 contributes to functional diversity of tumor-infiltrating neutrophils: A new target for cancer immunotherapy

Tavukcuoglu E., ESENDAĞLI G.
DEVELOPMENTAL CELL , cilt.60, sa.3, ss.339-341, 2025 (SCI-Expanded, Scopus)

9. S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling

Özbay Kurt F. G., Cicortas B., Balzasch B. M., De La Torre C., Ast V., Tavukcuoglu E., et al.
Journal for ImmunoTherapy of Cancer , cilt.12, sa.9, 2024 (SCI-Expanded, Scopus)

10. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles

Tonbul H., Şahin A., Öztürk S. C., Ultav G., Tavukçuoğlu E., Akbaş S., et al.
Journal of Drug Targeting , cilt.32, sa.9, ss.1101-1110, 2024 (SCI-Expanded, Scopus)

11. Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination

Tavukcuoglu E., Yanik H., Parveen M., Uluturk S., DURUSU TANRIÖVER M., İNKAYA A. Ç., et al.
Scientific Reports , cilt.13, sa.1, 2023 (SCI-Expanded, Scopus) Creative Commons License

12. Immune checkpoint status and exhaustion-related phenotypes of CD8+ T cells from the tumor-draining regional lymph nodes in breast cancer

Yilmaz I., Tavukcuoglu E., Horzum U., Yilmaz K. B., Akinci M., Gulcelik M. A., et al.
Cancer Medicine , cilt.12, sa.24, ss.22196-22205, 2023 (SCI-Expanded, Scopus)

13. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Anthiya S., ÖZTÜRK S. C., Yanik H., Tavukcuoglu E., ŞAHİN A., Datta D., et al.
Journal of Controlled Release , cilt.357, ss.67-83, 2023 (SCI-Expanded, Scopus)

14. A novel combination for the treatment of small cell lung cancer: Active targeted irinotecan and stattic co-loaded PLGA nanoparticles

Arslan F. B., ÖZTÜRK K., Tavukçuoğlu E., ÖZTÜRK S. C., ESENDAĞLI G., ÇALIŞ S.
International Journal of Pharmaceutics , cilt.632, 2023 (SCI-Expanded, Scopus)

15. Effects of Particle Geometry for PLGA-Based Nanoparticles: Preparation and In Vitro/In Vivo Evaluation

Kaplan M., ÖZTÜRK K., ÖZTÜRK S. C., Tavukçuoğlu E., ESENDAĞLI G., ÇALIŞ S.
Pharmaceutics , cilt.15, sa.1, 2023 (SCI-Expanded, Scopus) Creative Commons License

16. Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression

Unver N., Tavukcuoglu E., Esendagli G.
Life Sciences , cilt.311, 2022 (SCI-Expanded, Scopus)

17. Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination

Hafızoğlu M., Bas A. O., Tavukçuoğlu E., Sahiner Z., Oytun M. G., Ulutürk S., et al.
Clinical Immunology Communications , cilt.2, ss.154-158, 2022 (Scopus)

18. pH-sensitive chitosan-PEG-decorated hollow mesoporous silica nanoparticles could be an effective treatment for acute myeloid leukemia (AML)

Ultav G., Tonbul H., Tavukcuoglu E., Ozturk S. C., Akbas S., Sahin A., et al.
JOURNAL OF NANOPARTICLE RESEARCH , cilt.24, sa.2, 2022 (SCI-Expanded, Scopus)

19. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes

KURŞUNEL M. A., Taskiran E. Z., Tavukcuoglu E., Yanik H., Demirag F., KARAOSMANOĞLU B., et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY , cilt.71, sa.2, ss.445-459, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

20. Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier

Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.66, 2021 (SCI-Expanded, Scopus)

21. Functional responsiveness of memory T cells from COVID-19 patients

Tavukcuoglu E., Horzum U., İNKAYA A. Ç., ÜNAL S., ESENDAĞLI G.
CELLULAR IMMUNOLOGY , cilt.365, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells

TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.63, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

23. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer

Tavukcuoglu E., Horzum U., Yanik H., ÜNER A., Yoyen-Ermis D., NURAL S. K., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY , cilt.50, sa.12, ss.2067-2074, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Design and synthesis of novel peptidomimetics for cancer immunotherapy

Kose C., Uysal E., Yazici B., Tugay Z., Dingis-Birgul S. I., Yanik H., et al.
ORGANIC COMMUNICATIONS , cilt.13, sa.3, ss.89-102, 2020 (ESCI, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

25. Development and in vitro evaluation of a new adjuvant system containing Salmonella Typhi porins and chitosan

YÜKSEL S., PEKCAN M., PURALI N., ESENDAĞLI G., Tavukcuoglu E., Rivero-Arredondo V., et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS , cilt.578, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

26. Aggregation of chitosan nanoparticles in cell culture: Reasons and resolutions

Ozturk K., Arslan F. B., Tavukcuoglu E., ESENDAĞLI G., ÇALIŞ S.
INTERNATIONAL JOURNAL OF PHARMACEUTICS , cilt.578, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. PD-L2(+) wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses

Tavukcuoglu E., Horzum U., Yilmaz K. B., ESENDAĞLI G.
IMMUNOLOGY AND CELL BIOLOGY , cilt.98, sa.2, ss.152-164, 2020 (SCI-Expanded, Scopus)

28. Protocol to assess the suppression of T-cell proliferation by human MDSC

Bruger A. M., Vanhaver C., Bruderek K., Amodio G., Tavukcuoglu E., ESENDAĞLI G., et al.
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - CELLULAR METHODS, PT B , cilt.632, ss.155-192, 2020 (SCI-Expanded, Scopus)

29. Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer

Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.54, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS

Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., et al.
SCIENTIFIC REPORTS , cilt.9, 2019 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

31. A Novel Missense LIG4 Mutation in a Patient With a Phenotype Mimicking Behcet's Disease

Taskiran E., Sonmez H., Kosukcu C., Tavukcuoglu E., Yazici G., Esendagli G., et al.
JOURNAL OF CLINICAL IMMUNOLOGY , cilt.39, sa.1, ss.99-105, 2019 (SCI-Expanded, Scopus)

32. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

Kwa M., Li X., Novik Y., Oratz R., Jhaveri K., Wu J., et al.
Breast Cancer Research and Treatment , cilt.168, sa.1, ss.57-67, 2018 (SCI-Expanded, Scopus)

33. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells

Özkazanç D., Yöyen-Ermiş D., Tavukçuoğlu E., BÜYÜKAŞIK Y., ESENDAĞLI G.
IMMUNOLOGY , cilt.149, sa.4, ss.460-471, 2016 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 9

1. Otoimmün Kökenli Merkezi Sinir Sistemi Hastaliklarinda B Hücrelerin İmmünfenotiplendirilmesi

KURAL MANGIT E., TAVUKÇUOĞLU DEMİR E., ACAR ÖZEN N. P., ESENDAĞLI G., TUNCER M. A.
12. NÖROİMMÜNOLOJİ OKULU, Kıbrıs (Kktc), 8 - 11 Mayıs 2025, (Özet Bildiri)

2. TARGETING PLGA-PEG NANOPARTICLES TO SMALL CELLLUNG CANCER (SCLC) USING ANTIBODIES AND ANTIBODY FRAGMENTS

Arslan F. B., ÖZTÜRK K., Tavukçuoğlu E., ÇALIŞ S.
20th International Pharmaceutical Technology Symposium, 21 Şubat 2022, (Tam Metin Bildiri)

3. Antiretroviral therapy causes a reduction in T-cell exhaustion, which is preserved after switching to a new therapy regimen

Özcan B., Tavukçuoğlu E., KARA E., Horzum U., AYAN G., SÖNMEZER M. Ç., et al.
18th European AIDS Conference (EACS 2021), London, Kanada, 27 Ekim 2021, cilt.1, ss.52-53, (Tam Metin Bildiri)

4. A Modified Cell Culture Method for Evaluation of Chitosan Nanoparticles

ÖZTÜRK K., Arslan F. B., Tavukçuoğlu E., ESENDAĞLI G., ÇALIŞ S.
8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019, (Tam Metin Bildiri)

5. Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin İn Breast Cancer

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., et al.
8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 Ekim 2019, cilt.1, ss.184-186, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

6. In Vitro Activation Of Murine Macrophages by Adjuvant System Composed Of Chitosan And Porins

Yüksel S., Pekcan M., Özkul A., Puralı N., Esendağlı G., Tavukçuoğlu E., et al.
EUFEPS Annual Meeting 2019, Frankfurt, Almanya, 6 - 08 Mart 2019, ss.1, (Özet Bildiri)

7. In Vitro Evaluation of Porin Encapsulated Chitosan Nanosystems for Mucosal Vaccine Delivery

Yüksel S., Pekcan M., Puralı N., Özkul A., Esendağlı G., Tavukçuoğlu E., et al.
AAPS PharmSci 360, Washington, Amerika Birleşik Devletleri, 4 - 07 Kasım 2018, ss.1, (Özet Bildiri) Sürdürülebilir Kalkınma

8. Analysis of spleen-derived MDSCs in pancreatic and gastric cancer patients

tavukcuoglu E., horzum u., Yoyen-Ermis D., aydın b., Yılmaz B. K., ÜNER A., et al.
1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 Kasım 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

9. PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES

TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu E., AKTAŞ Y., et al.
19th InternationalPharmaceutical Technology Symposium-IPTS 2018, 17 - 19 Eylül 2018, (Tam Metin Bildiri)
Kitaplar 1

1. Cytotoxicity and Biological Compatibility

Tavukcuoglu E., Yanik H., ESENDAĞLI G.
Drug Delivery with Targeted Nanoparticles: In Vitro and in Vivo Evaluation Methods, Taylor & Francis Ltd, ss.223-246, 2021
Metrikler

Yayın

43

Yayın (WoS)

32

Yayın (Scopus)

34

Atıf (WoS)

141

H-İndeks (WoS)

7

Atıf (Scopus)

765

H-İndeks (Scopus)

16

Atıf (Scholar)

257

H-İndeks (Scholar)

10

Açık Erişim

6
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER
SDG 16: AMAÇ 16: BARIŞ VE ADALET